APPENDIX IA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018

1.

BASIS OF PREPARATION

Shanghai Junshi Biosciences Co., Ltd (the “Company”) was established in the People’s Republic of China (the
“PRC”) on December 27, 2012 and converted into a joint stock company with limited liability in May 2015. In August
2015, the Company was listed on the National Equities Exchange and Quotations (“NEEQ”) (stock code 833330). The
condensed consolidated financial statements are presented in Renminbi (“RMB”) which is also the functional
currency of the Company.

The principal activities of the Company and its subsidiaries (the “Group”) are mainly discovery, development

and commercialisation of innovative drugs.

The condensed consolidated financial statements have been prepared in accordance with International
Accounting Standard 34 (“IAS 34”) Interim Financial Reporting issued by the International Accounting Standards
Board (“IASB”) as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited.

Significant transactions in the current interim period

The Group completed the disposal of the segment of sales of biological reagent during the current interim
period, resulting a gain on disposal of approximately RMB441,000. Details of the disposal are set out in Note 7.

The Group also entered into a collaboration agreement and details are set out in Note 16A.

On August 23, 2018, TopAlliance Biosciences Inc. (“TopAlliance”), a subsidiary of the Company, entered into
a Patent and Technology License Agreement (“Agreement”) with the Board of Regents of The University of Texas
System (“System Board”) on behalf of The University of Texas Health Science Center at Houston, under which
System Board granted TopAlliance a royalty-bearing non-exclusive license for certain patent right related to
monoclonal antibodies against EGFL6 for diagnostic and cancer therapeutic use and technology right related to
EGFL6-Binding antibodies and the use of thereof. On September 7, 2018, TopAlliance paid USD2,500,000
(equivalent to approximately RMB17,053,000) non-refundable and non-creditable upfront fees to System Board upon
entering into the agreement. TopAlliance is also obligated to make up to USD6,000,000 (equivalent to approximately
RMB41,659,000) milestone payments upon regulatory approval in China and up to USD31,000,000 (equivalent to
approximately RMB215,236,000) milestone payments upon regulatory approval in territories other than China and
royalty payments at the applicable royalty rate based on the net sales of the licensed product upon commercialisation.
The upfront payments was recognised as research and development expenses during the nine months ended
September 30, 2018.

2.

PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis, except for

certain financial instruments, which are measured at fair values, as appropriate.

The accounting policies and methods of computation used in the condensed consolidated financial statements
for the nine months ended September 30, 2018 are the same as those followed in the preparation of the Group’s
historical financial information for the two years ended December 31, 2017 and the six months ended June 30, 2018
(“Historical Financial Information”) included in the accountant’s report as set out in Appendix I to this prospectus.

3.

REVENUE AND SEGMENT INFORMATION

An analysis of the Group’s revenue for the period is as follows:

For the three months
ended September 30,

For the nine months
ended September 30,

2018

2017

2018

2017

RMB’000
(Unaudited)

RMB’000
(Unaudited)

RMB’000
(Unaudited)

RMB’000
(Unaudited)

–

–

–

1,148

Continuing operations
Consultancy service fee income

– at a point in time

– IA-8 –

